Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...

After Summit Therapeutics (NASDAQ:SMMT) said early this week that its lead asset ivonescimab outperformed Merck's (NYSE:MRK) ...

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC. Wednesday, the FDA approved Merck ...

Merck & Co is on the brink of plugging a gap in the coronavirus treatment armamentarium after its oral drug molnupiravir cut deaths and hospitalisations in mild or moderate COVID-19 in a phase 3 ...

Atea has struggled to demonstrate bemnifosbuvir’s COVID potential in the past, including in a phase 2 trial back in the midst ...

On the efficacy issue, Merck told ... develop severe COVID-19 than men. On the other hand, there were also more older people later on, which should have benefited the active drug.

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

"It is rare for a cardio-metabolic drug to modify non-cardiovascular outcomes. The fact that semaglutide reduced non-cardiovascular death, and in particular COVID-19-related deaths, was surprising.